Skip to main
AUPH
AUPH logo

Aurinia Pharmaceuticals (AUPH) Stock Forecast & Price Target

Aurinia Pharmaceuticals (AUPH) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 67%
Buy 0%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Aurinia Pharmaceuticals is projected to generate significant revenue growth, with risk-adjusted product revenues expected to reach $243.7 million in 2025 and soar to $932.3 million by 2033. Additionally, the projected revenue from aritinercept reflects potential growth from $15.4 million in 2030 to $281.6 million by 2033, contingent on successful market entry. Furthermore, the anticipated positive impact of the 2024 ACR LN guideline is expected to enhance the growth trajectory of LUPKYNIS starting in 2027, indicating robust future demand for the company's therapies.

Bears say

Aurinia Pharmaceuticals has demonstrated challenges in maintaining consistent sales growth, which raises concerns regarding its financial sustainability amidst a competitive biopharmaceutical landscape. The reported increase in adverse effects related to its marketed product, LUPKYNIS, may adversely impact patient adherence and market perception, further complicating future revenue generation. Additionally, ongoing developmental costs associated with its pipeline product, AUR200, could strain financial resources, potentially limiting the company’s ability to achieve profitability in the near term.

Aurinia Pharmaceuticals (AUPH) has been analyzed by 3 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 0% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Aurinia Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Aurinia Pharmaceuticals (AUPH) Forecast

Analysts have given Aurinia Pharmaceuticals (AUPH) a Buy based on their latest research and market trends.

According to 3 analysts, Aurinia Pharmaceuticals (AUPH) has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Aurinia Pharmaceuticals (AUPH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.